Collegium Pharmaceutical Inc. (COLL)
Summary
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
Collegium Pharmaceutical, Inc. (COLL) Q2 2026 Earnings Call Transcript
Collegium Pharmaceutical (COLL) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Collegium Pharmaceutical (COLL) give a sense of how its business performed in the quarter ended June 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Collegium Pharmaceutical (COLL) Beats Q2 Earnings and Revenue Estimates
Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.92 per share, beating the Zacks Consensus Estimate of $1.68 per share. This compares to earnings of $1.68 per share a year ago.
Collegium Pharmaceutical Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Curtis Ellergodt Rothschild Investment LLC | 87 | $2,945.24 | $2,783.13 | -$162.11 | -5.5% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 99 | $3,775.23 | $2,572.02 | -$1,203.21 | -31.87% |
| SN Stephanie Nee HARBOR CAPITAL ADVISORS Inc. | 24,799 | $820,991.43 | $730,826.53 | -$90,164.9 | -10.98% |
| BG Bart Gancher Intech Investment Management LLC | 38,092 | $1.51M | $1.12M | -$385,284.43 | -25.55% |
| JM John Malone Amundi | 23,492 | $824,882.12 | $638,982.4 | -$185,899.72 | -22.54% |
Collegium Pharmaceutical Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Glen Santangelo Barclays | 140.25 | $4,030.82 | $3,835.87 | -$194.95 | -4.84% |
Collegium Pharmaceutical Inc. (COLL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Collegium Pharmaceutical Inc. ever had a stock split?
Collegium Pharmaceutical Inc. Profile
| Specialty Retail Industry | Consumer Discretionary Sector | Vikram Karnani CEO | NASDAQ (NGS) Exchange | 19459J104 CUSIP |
| US Country | 423 Employees | - Last Dividend | - Last Split | 7 May 2015 IPO Date |
Overview
Collegium Pharmaceutical, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative medicines for pain management. Since its establishment in 2002 and subsequent name change in 2003, the company has dedicated its efforts towards providing solutions for patients suffering from pain. Headquartered in Stoughton, Massachusetts, Collegium Pharmaceutical aims to introduce abuse-deterrent formulations that offer effective pain relief while addressing the significant concern of opioid misuse. The company's expertise lies in leveraging its technological advancements to develop medicines that are not only effective in managing severe and persistent pain but also in mitigating the risks associated with long-term opioid use.
Products and Services
- Xtampza ER
An abuse-deterrent, extended-release oral formulation of oxycodone designed for managing pain that requires daily, around-the-clock, long-term opioid treatment. By employing an abuse-deterrent mechanism, Xtampza ER provides an option for those in severe pain, simultaneously addressing concerns related to opioid misuse.
- Nucynta ER and Nucynta IR
These formulations of tapentadol come in both extended-release (ER) and immediate-release (IR) forms. They are intended for the management of acute, severe, and persistent pain, offering versatility in pain management strategies to accommodate different levels of pain severity and durations.
- Belbuca
A buccal film containing buprenorphine, designed for the treatment of pain. Belbuca offers an innovative delivery system that allows for the efficient and controlled release of buprenorphine, a potent opioid that can provide long-term relief from chronic pain.
- Symproic
An oral formulation of naldemedine aimed at treating opioid-induced constipation in adult patients with chronic non-cancer pain. Symproic addresses a common and often distressing side effect of long-term opioid use, thereby improving the quality of life for patients undergoing long-term opioid therapy.
